DrugPatentWatch Database Preview
NUVESSA Drug Profile
Email this page to a colleague
» See Plans and PricingWhen do Nuvessa patents expire, and what generic alternatives are available?
Nuvessa is a drug marketed by Chemo Research Sl and is included in one NDA. There are six patents protecting this drug.
This drug has sixteen patent family members in nine countries.
The generic ingredient in NUVESSA is metronidazole. There are eighteen drug master file entries for this compound. Fifty-nine suppliers are listed for this compound. Additional details are available on the metronidazole profile page.
US ANDA Litigation and Generic Entry Outlook for Nuvessa
A generic version of NUVESSA was approved as metronidazole by TEVA PHARMS USA on November 6th, 1984.
Summary for NUVESSA
| International Patents: | 16 |
| US Patents: | 6 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 125 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | NUVESSA at DailyMed |
Pharmacology for NUVESSA
| Drug Class | Nitroimidazole Antimicrobial |
US Patents and Regulatory Information for NUVESSA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chemo Research Sl | NUVESSA | metronidazole | GEL;VAGINAL | 205223-001 | Mar 24, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Chemo Research Sl | NUVESSA | metronidazole | GEL;VAGINAL | 205223-001 | Mar 24, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Chemo Research Sl | NUVESSA | metronidazole | GEL;VAGINAL | 205223-001 | Mar 24, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Chemo Research Sl | NUVESSA | metronidazole | GEL;VAGINAL | 205223-001 | Mar 24, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Chemo Research Sl | NUVESSA | metronidazole | GEL;VAGINAL | 205223-001 | Mar 24, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for NUVESSA
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2009097143 | Start Trial |
| China | 103763925 | Start Trial |
| Japan | 6235087 | Start Trial |
| Canada | 3054236 | Start Trial |
| Australia | 2012275292 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for NUVESSA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0328535 | 96C0021 | Belgium | Start Trial | PRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
